This is an appeal from dismissal of an antitrust action pursuant to Fed.R.Civ.P. 12(b)(6), for failure to state a claim upon which relief can be granted,
I.
A.
Since the district court rendered judgment at the pleading stage, we must accept as true the facts alleged in the complaint.
Hiskon v. King & Spalding,
Armatures are necessary components of fractional power commutator motors used in most small household appliances. To manufacture armatures efficiently the manufacturer must use an armature winding machine. The plaintiff, Axis, is an Italian corporation that manufactures armature winding machines and sells them to electrical appliance manufacturers throughout Europe. The defendant, Micafil, is a United States corporation that has manufactured and sold armature winding machines in the United States since 1985. Mi-cafil is a wholly-owned subsidiary of Micaf-il, A.G., a Swiss corporation that manufactures and sells armature winding machines throughout Europe.
An armature winding machine winds copper wire around an armature arm to form a coil. The machine attaches the wire to a commutator and then cuts the wire. In the 1970s Globe Tool & Engineering Co. (Globe) and Possis Corporation (Possis) obtained United States patents on the only two wire cutting methods used in armature winding machines. In 1976 Globe and Pos-sis granted each other a non-exclusive license “to make, have made, use, lease and sell” devices and methods falling within the scope of their patents. Sometime later Possis granted similar licenses to Ott-A-Matic, Inc. (Ott) and Mechaneer, Inc. (Me-chaneer). In 1985, prior to Micafil’s entry into the market, four companies manufactured and sold armature winding machines in the United States: Possis, Globe, Ott and Mechaneer. Three companies engaged in the same activities outside the United States: Axis, Micafil and Odawara, a Japanese corporation.
Prior to 1985 Possis refused to grant a license to any of the foreign armature winding machine manufacturers though all three sought such licenses. In July 1985, however, Possis sold its assets, including the patents and licenses covering armature winding machines, to Micafil. Micafil then entered the U.S. market. Shortly thereafter Axis learned that Micafil was attempting to purchase Mechaneer. When the president of Axis approached Mecha-neer to determine whether Mechaneer was for sale, that company’s principals refused to discuss the possibility of selling to Axis because Mechaneer’s negotiations with Mi-cafil were almost complete. Micafil bought Mechaneer in September 1985. Axis was ready, willing and able to purchase Mecha-neer for the same price that Micafil paid. The two purchases enabled Micafil to control approximately 50% of the U.S. armature winding machine market (Possis had about 40% and Mechaneer about 10%).
At some unspecified time Odawara purchased Ott. As a result of the various acquisitions, the number of armature winding machine manufacturers in the United States shrunk from four to three. These three competitors, Globe, Micafil and Oda-wara, now own all the patents and licenses governing the manufacture of armature winding machines in the United States.
B.
While alleging in its complaint that “the acquisition of Mechaneer by Micafil raised substantially the barriers to entry into the U.S. market for manufacture and sale of armature winding machines for all potential manufacturers, particularly Axis, and indeed, has prevented Axis’ entry into the market,” Axis also stated that “the Possis patents now owned by Micafil” are “[t]he only thing[s] preventing” Axis’ entry into the market. The complaint charged Micafil with violating the antitrust laws by acquiring Mechaneer because the acquisition brought about a substantial reduction of competition in the market. Axis also alleged that by reason of the acquisitions it *1107 had suffered lost sales and lost profits from winding machines that it would have sold in the United States had Micafil not purchased Mechaneer. In addition to treble damages under § 4, Axis sought an injunction under § 16 of the Clayton Act requiring Micafil either to divest itself of Mechaneer or to grant Axis express licenses to the Possis patents.
In granting Micafil’s motion to dismiss, the district court assumed that the Mecha-neer acquisition violated both § 1 of the Sherman Act and § 7 of the Clayton Act, as Axis claimed. Nevertheless, the court found that the complaint failed to state a claim because it did not allege an “antitrust injury.” The court concluded that Axis would have suffered the same injury — exclusion from the U.S. market — if Micafil had not purchased Mechaneer. The Possis and Globe patents, not the purchase of Mechaneer, foreclosed Axis’ entry into the market. Thus, the anticompetitive act of purchasing Mechaneer did not cause the plaintiff’s alleged injury. The patents were an impenetrable barrier to the plaintiff’s entry before Micafil purchased Me-chaneer, and they remained as great a barrier afterwards. The district court also recognized that Odawara had been able to enter the U.S. market by purchasing Ott, an effort Axis apparently never made. This acquisition could have caused Axis’ alleged injury. Thus, the court concluded, any injury that Axis may have suffered did not flow directly from Micafil’s presumably unlawful act.
II.
The Clayton Act uses very broad language to describe who may bring private actions for antitrust violations. Section 4 states that “any person who shall be injured in his business or property by reason of anything forbidden in the antitrust laws may sue ... and shall recover threefold the damages by him sustained.” Section 16 provides that “[a]ny person, firm, corporation, or association shall be entitled to sue for and have injunctive relief ... against threatened loss or damage by a violation of the antitrust laws.”
Despite the statute s all-encompassing language, the Supreme Court has determined that claims of injury by reason of antitrust violations are compensable only when the injury flows directly from the unlawful act. The Court noted in
Hawaii v. Standard Oil Co.,
The Supreme Court subjected a § 4 claim for treble damages to this analysis in
Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc.,
The Court defined this limitation on the right to recover treble damages for § 7 violations [acquisitions whose effect “may be substantially to lessen competition, or to tend to create a monopoly”] as follows:
We therefore hold that for plaintiffs to recover treble damages on account of § 7 violations, they must prove more than injury causally linked to an illegal presence in the market. Plaintiffs must prove antitrust injury, which is to say injury of the type the antitrust laws were intended to prevent and that flows from that which makes defendants’ acts unlawful. The injury should reflect the anticompetitive effect either of the violation or of anticompetitive acts made possible by the violation. It should, in short, be “the type of loss that the claimed violations ... would be likely to cause.” Zenith Radio Corp. v. Hazeltine Research, 395 U.S. [100] at 125 [89 S.Ct. 1562 at 1577,23 L.Ed.2d 129 ].
Id.
at 489,
In
Cargill, Inc. v. Monfort of Colorado, Inc.,
III.
The parties repeat in this court the arguments they made in the district court. We will discuss the plaintiff-appellant’s position in detail.
Axis insists that the district court misconstrued its complaint and misread decisions of the Supreme Court, this court, and other federal courts. Axis contends that the standard applied by the district court in this case would preclude almost all private antitrust actions. It interprets the district court opinion to hold that an antitrust plaintiff must show “not only that its injury flowed from the violation, but also that its injury could not have occurred under any alternative set of facts that did not include an antitrust violation.”
A.
Axis argues for a very narrow application of
Brunswick.
The acquisitions of the failing bowling alleys by Brunswick increased or at least maintained the level of competition in the relevant market. From this fact, Axis argues that
Brunswick
never precludes recovery for failure to allege antitrust injury when the plaintiff claims that the challenged acquisition reduces competition. While the fact that Brunswick’s acquisitions would not reduce competition was certainly an important element of the
Brunswick
decision, that was not the only decisive factor. For purposes of the present case, another element of the decision is equally important. Aside from the acquisitions’ effect on competition, the Court found no antitrust injury because the plaintiffs’ injury, while causally connected to the acquisitions, was not caused by “that which made the acquisitions unlawful.”
Axis seeks to support its position by citing two of the Supreme Court’s post-
Brunswick
decisions, one of which dealt with § 4 antitrust standing and the other with § 16 antitrust injury. Antitrust injury is a concept distinct from antitrust
*1109
standing, but is an element in the determination of standing. Thus, even where there is antitrust injury, a plaintiff may be found to lack standing because other elements of the standing equation are missing. See
Cargill, Inc. v. Monfort of Colorado, Inc.,
B.
Axis first relies on
Blue Shield of Virginia v. McCready,
Although not explicitly stated in the opinion,
Associated General Contractors, Inc. v. California State Council of Carpenters,
Axis also relies on
Cargill, Inc. v. Monfort of Colorado, Inc.,
*1110
Axis also contends that the district court erred in relying on
Alberta Gas Chemicals, Ltd. v. E.I. Du Pont de Nemours & Co.,
The court assumed that the acquisition was illegal because it gave Du Pont the power to prevent Conoco from entering the methanol-producing industry as an independent competitor. In other words, it reduced competition in that industry. The court, however, found that the loss of anticipated sales from the cancelled “demand creation” activities of Conoco did “not flow ‘from that which makes the defendants’ acts unlawful.’ ”
Id.
at 1241, quoting
Brunswick,
We have not found a helpful Sixth Circuit case. In
Langenderfer, Inc. v. S.E. Johnson Co.,
In
Bayou Bottling, Inc. v. Dr. Pepper Co.,
Bayou would have suffered the identical loss of sales, and economies of scale if [the competitor] had retained his operation or if he had sold to a third party. The injury does not satisfy either prong of the Brunswick test; it is not the type of injury the antitrust laws were designed to prevent and it does not flow from that which ostensibly made the defendants’ activities illegal.
Id. at 304. The district court applied the same analysis to Axis’ claim in the present case.
C.
Many of Micafil’s arguments appear to confuse antitrust injury with antitrust standing. This confusion occurs because
*1111
the two concepts “share a common ingredient.”
Triple M Roofing Corp. v. Tremco, Inc.,
IV.
We agree with the district court. Viewing the complaint in the light most favorable to Axis, the complaint does not allege an antitrust injury. As Axis admitted in the complaint itself, the Possis and Globe patents precluded its entry into the U.S. market. The cases cited by Axis for the general proposition that a patent holder may violate antitrust laws by misusing his patents in an attempt to create an unlawful monopoly cast no light on the issue in this case. See
SCM Corp. v. Xerox Corp.,
Our patent and antitrust laws seek to further different and opposing policies. Patent laws grant a monopoly for a limited time in order “[t]o promote the Progress of Science and useful Arts_” U.S. Const. Art. I, § 8, cl. 8. Antitrust laws, on the other hand, are designed to promote and protect competition in the marketplace. Thus, a lawfully acquired patent creates a monopoly that does not violate the antitrust laws. While patent abuse may constitute an antitrust violation,
United States v. Westinghouse Electric Corp.,
This is not a case where a patent holder has attempted “to monopolize an industry by acquiring all present and future patents relevant to that industry.”
Id.
Globe still owns patents and Odawara operates in the U.S. market under licenses granted by Pos-sis to Ott prior to Odawara’s acquisition of Ott. The charge that Micafil “raised the barriers” to Axis’ entry into the U.S. market by acquiring Possis and Mechaneer fails to allege antitrust injury, however, since Micafil never dominated the U.S. market for armature winding machines as Xerox did the market for plain paper copying machines in
SCM Corp. v. Xerox Corp.
The
SCM
court carefully delineated the conditions under which the acquisition of patents may violate the antitrust laws and create antitrust injury for which damages may be awarded.
CONCLUSION
Axis alleged no more than a causal link between Micafil’s acquisition of Possis and Mechaneer and its claimed injury. What made the acquisition illegal was that by acquiring Mechaneer, Micafil further reduced competition in an industry that was already served by very few manufacturers. As did the plaintiffs in
Brunswick, Alberta Gas,
and
Bayou Bottling,
however, Axis would have suffered the same injury if Mechaneer had remained in business or if some entity other than Micafil had purchased Mechaneer. Perhaps a consumer or a competitor could state a claim for dam
*1112
ages and injunctive relief on the basis of the Mechaneer acquisition, but Axis did not. The injury for which it sought relief was not inflicted by reason of Micafil’s newly-acquired position in the market and the elimination of one competitor. The patents and licenses owned and possessed by three companies — Globe, Odawara and Mi-cafil — not by Micafil alone, precluded Axis’ entry into the U.S. market for armature winding machines. Thus, Axis’ alleged injury is not “of the type the antitrust laws were intended to prevent” and it did not “flow from” the element of the acquisition that made it unlawful.
Brunswick,
The judgment of the, district court is affirmed.
